Literature DB >> 2878813

Stereo- and regioselectivity of hepatic oxidation in man--effect of the debrisoquine/sparteine phenotype on bufuralol hydroxylation.

P Dayer, T Leemann, A Küpfer, T Kronbach, U A Meyer.   

Abstract

The influence of the debrisoquine/sparteine-type of oxidation polymorphism on plasma bufuralol concentration and the pattern of urine metabolites was studied in extensive and poor metabolizer subjects. (+)- and (-)-bufuralol, and (+)- and (-)-OH-bufuralol in plasma were determined by enantioselective HPLC, and urinary bufuralol and its metabolites were assayed by gas chromatography-mass spectrometry. Three hours after administration of racemic bufuralol the plasma (-)/(+) isomeric ratio for unchanged bufuralol was 1.84 in extensive metabolizers, indicating preferential clearance of the (+)-isomer through aliphatic 1'-hydroxylation and glucuroconjugation, while the (-)-isomer was mainly eliminated by aromatic 4-hydroxylation. Poor metabolizers were characterized by impaired 1'- and 4-hydroxylation, with almost total abolition of the stereoselectivity of these reactions. The data strongly suggest that both 1'- and 4-hydroxylation are catalyzed by the same enzyme. These in vivo observations are in agreement with recent in vitro data obtained in human liver microsomes from phenotyped patients and support the concept of deficiency of a highly stereoselective cytochrome P-450 isozyme as the cause of this polymorphism.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2878813     DOI: 10.1007/bf00981130

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  21 in total

Review 1.  The polymorphic oxidation of beta-adrenoceptor antagonists. Clinical pharmacokinetic considerations.

Authors:  M S Lennard; G T Tucker; H F Woods
Journal:  Clin Pharmacokinet       Date:  1986 Jan-Feb       Impact factor: 6.447

2.  Stereochemistry, a basis for sophisticated nonsense in pharmacokinetics and clinical pharmacology.

Authors:  E J Ariëns
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

3.  Hepatic monooxygenase activities in subjects with a genetic defect in drug oxidation.

Authors:  P J Meier; H K Mueller; B Dick; U A Meyer
Journal:  Gastroenterology       Date:  1983-09       Impact factor: 22.682

Review 4.  Defective oxidation of drugs: pharmacokinetic and therapeutic implications.

Authors:  M Eichelbaum
Journal:  Clin Pharmacokinet       Date:  1982 Jan-Feb       Impact factor: 6.447

5.  Effect of oxidative polymorphism (debrisoquine/sparteine type) on hepatic first-pass metabolism of bufuralol.

Authors:  P Dayer; L Balant; A Kupfer; R Striberni; T Leemann
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

6.  The genetic control of bufuralol metabolism in man.

Authors:  P Dayer; L Balant; F Courvoisier; A Kupfer; A Kubli; A Gorgia; J Fabre
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1982 Jan-Mar       Impact factor: 2.441

7.  Polymorphic dextromethorphan metabolism: co-segregation of oxidative O-demethylation with debrisoquin hydroxylation.

Authors:  B Schmid; J Bircher; R Preisig; A Küpfer
Journal:  Clin Pharmacol Ther       Date:  1985-12       Impact factor: 6.875

8.  Bufuralol metabolism in human liver: a sensitive probe for the debrisoquine-type polymorphism of drug oxidation.

Authors:  E I Minder; P J Meier; H K Müller; C Minder; U A Meyer
Journal:  Eur J Clin Invest       Date:  1984-06       Impact factor: 4.686

9.  The molecular mechanisms of two common polymorphisms of drug oxidation--evidence for functional changes in cytochrome P-450 isozymes catalysing bufuralol and mephenytoin oxidation.

Authors:  U A Meyer; J Gut; T Kronbach; C Skoda; U T Meier; T Catin; P Dayer
Journal:  Xenobiotica       Date:  1986-05       Impact factor: 1.908

10.  Genetic polymorphism in drug oxidation: in vitro studies of human debrisoquine 4-hydroxylase and bufuralol 1'-hydroxylase activities.

Authors:  A R Boobis; S Murray; C E Hampden; D S Davies
Journal:  Biochem Pharmacol       Date:  1985-01-01       Impact factor: 5.858

View more
  3 in total

Review 1.  Designing safer (soft) drugs by avoiding the formation of toxic and oxidative metabolites.

Authors:  Nicholas Bodor; Peter Buchwald
Journal:  Mol Biotechnol       Date:  2004-02       Impact factor: 2.695

2.  Neutrophil Microparticles Deliver Active Myeloperoxidase to Injured Mucosa To Inhibit Epithelial Wound Healing.

Authors:  Thomas W Slater; Ariel Finkielsztein; Lorraine A Mascarenhas; Lindsey C Mehl; Veronika Butin-Israeli; Ronen Sumagin
Journal:  J Immunol       Date:  2017-02-27       Impact factor: 5.422

Review 3.  Clinical significance of genetic influences on cardiovascular drug metabolism.

Authors:  L Arcavi; N L Benowitz
Journal:  Cardiovasc Drugs Ther       Date:  1993-06       Impact factor: 3.727

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.